Anneli Waara

It is a well-known from drug trials that individuals can respond just as well to placebos, sugar pills, as to the active drug. On the other hand, it is difficult to explain why only certain people get better from placebos. A team of researchers from Uppsala University and Gothenburg University have now found gene variants that can impact the placebo effect and a mechanism in the brain that characterizes those who respond to placebos.
The study, published in Journal of Neuroscience, examined 108 individuals suffering from social phobia using positron emission tomography (PET) scanning. The individuals were participating in a treatment study looking into how anxiety-moderating drugs affect brain activity. Just under a quarter of the subjects were given a placebo instead of an active drug. This was a double-blind study so neither the subjects nor the research team knew who was taking the drug or the sugar pill.
Before and after an eight-week period of treatment, the participants were asked to give a stressful oral presentation while their brain activity was monitored. Forty percent of the placebo group had received the same degree of anxiety relief from the sugar pill as other groups got from a drug.
Those who responded well to the placebo had a significant reduction in activity in the amygdalae in the temporal lobe, while this reduction was not found in the others. In previous research the amygdalae have stood out as key structures for emotional reactions. Both serotonin-active drugs (SSRI preparations) and cognitive behavioral therapy moderate activity in this area.
"Thus, successful placebo treatment works through the same mechanism in the brain," says Tomas Furmark at the Uppsala University Department of Psychology, who directed the study.
The study also analyzed two genes that influence the reabsorption and synthesis of serotonin in the brain (the serotonin transporter gene and the tryptophan hydroxylase-2 gene). The findings showed that only individuals who had certain variants (alleles) of these genes had reduced activity in the amygdala. The tryptophan hydroxylase-2 genes variants in particular predicted the degree of anxiety relief achieved by the placebo as well as moderation of the amygdala.
Statistical analyses found that it is a genetic effect on the activity in the amygdala that influences the propensity to respond to a placebo, that is, a path from the gene, via the brain, to behavior.
The study shows for the first time that genes influence the placebo effect by regulating reactions in an area of the brain that is important for our emotions.
This could have significant consequences for all drug testing and other treatment studies that use a placebo.
"The findings show that the possibilities of demonstrating that an active treatment functions better than a placebo can be affected by the gene variants in the trial subjects. It is also possible that genes can explain why certain people respond well or poorly to anxiety-moderating drugs and psychotherapy respectively," says Tomas Furmark.
Furmark T, Appel L, Henningsson S, A Link between Serotonin-Related Gene Polymorphisms, Amygdala Activity, and Placebo-Induced Relief from Social Anxiety. J Neurosci. 2008 Dec;28(49):13066-13074 [Abstract]